Loading clinical trials...
Loading clinical trials...
Malignant pleural mesothelioma (MPM) is a rare pleural cancer, which could be primary or secondary to an asbestos exposure. To enhance our knowledge of this rare disease, an exploration of genetic and tumor mechanism is mandatory. One of the principal difficulty is to harvest sufficient tumour pieces to perform multi-omics analysis. The goal of the SCITH-MESO study is to harvest larges pieces of tumour during a routine surgical procedure of MPM diagnosis by mean of pleural biopsies during VATS surgery. Operating samples will increase a tissue bank collection (CRB).
Age
18 - 95 years
Sex
ALL
Healthy Volunteers
No
Département de chirurgie thoracique
Bron, France
Start Date
February 11, 2022
Primary Completion Date
February 11, 2026
Completion Date
February 11, 2026
Last Updated
February 1, 2024
30
ESTIMATED participants
PLEURAL BIOCOLLECTION OF MALIGNANT PLEURAL MESOTHELIOMA
GENETIC
Lead Sponsor
Hospices Civils de Lyon
NCT06051695
NCT05538806
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06057935